Investigating Pathogenic and Hepatocarcinogenic Mechanisms from Normal Liver to HCC by Constructing Genetic and Epigenetic Networks via Big Genetic and Epigenetic Data Mining and Genome-Wide NGS Data Identification

Table 1

Network biomarkers for preventing the hepatocarcinogenesis of NAFLD&NASH and PBC&PSC.

	NAFLD&NASH to HCC	PBC&PSC to HCC
The highly activated network biomarkers for potential inhibition strategy of drug design	ACTA2, AIFM1, APP, EGFR, GRB2, NEDD8, SHC1, TUBA1C, TUBB6, IL4R, GPR37, FRAT2, HIST2H2BE, HSPB1, ZNF480, TIMP1, ALDOB, ZYX, YBX1, TP53, STAT5A, AR, TELO2, PXN, TBP, REPIN1, HSF1, ETS1, STUB1, RFC5, RPL30, TRMT1, GSK3B, UBC, ALB, and MIR21	ACTB, ADRB2, APP, CSNK2A1, EGFR, HUWE1, LMNB1, PCK1, PPP2CA, SMAD5, TSC22D1, ESR1, PGR, RYR2, FRAT2, HIST2H2BE, ZNF480, H3F3A, TIMP1, ALDOB, IGF2, AR, TP53, SRF, NRF1, STAT5A, RPL23A, SP1, SP3, CEBPA, BPTF, ETS1, MDC1, RFC5, RPL30, TRMT1, UBC, GSK3B, TF, and MIR21
The repressed network biomarkers for potential activation strategy of drug design	ALK and GATA1	CEBPE and GATA1